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Summary
Genomewide association studies are set to become the
tool of the future for detection of small-effect genes in
complex diseases. It will therefore be necessary to cal-
culate sufficient sample sizes with which to perform
them. In this paper I illustrate how to calculate the re-
quired number of families for general genotypic relative
risks (GRRs). I show the superior sensitivity of the ge-
nomewide association study over the standard genome-
wide affected-sib-pair linkage analysis, for a range of
different underlying GRR patterns. I also illustrate the
extent of change in the sample sizes that is necessary for
a genomewide association analysis depending on the pat-
tern of the GRRs at the disease locus. In many cases,
the comparative numbers of families required under dif-
ferent genetic mechanisms vary by several orders ofmag-
nitude. These sometimes dramatic differences have im-
portant implications for the determination of the size of
the collection of samples prior to analysis and for the
types of effects that are likely—and unlikely—to be de-
tected by such an analysis.
Introduction
It has been proposed (Risch and Merikangas 1996) that,
pending the existence of a map consisting of several bial-
lelic markers in each gene (∼1/kb), genomewide asso-
ciation studies will become not only a possibility but a
superior alternative to the standard genomewide af-
fected-sib-pair (ASP) linkage analyses. In their work,
Risch and Merikangas compared ASP linkage analysis
with association analysis (using the transmission/dis-
equilibrium test [TDT]; Spielman et al. 1993), for sen-
Received July 28, 1997; accepted for publication October 7, 1997;
electronically published December 12, 1997.
Address for correspondence and reprints: Dr. Nicola J. Camp, Sec-
tion of Molecular Medicine, M Floor, Royal Hallamshire Hospital,
University of Sheffield, Sheffield S10 2JF, United Kingdom. E-mail:
njc@mendel.shef.ac.uk
 1997 by The American Society of Human Genetics. All rights reserved.
0002-9297/97/6106-0028$02.00
sitivity in genomewide screens, but only under certain
simplifications. Specifically, they assumed that the set of
biallelic markers screened actually contained any disease
loci and, also, that a multiplicative relationship for the
genotypic relative risk (GRR) existed at those disease
loci. In a response to the Risch and Merikangas work,
Mu¨ller-Myhsok and Abel (1997) addressed the former
of these two assumptions and commented that, if less
than maximum linkage disequilibrium existed between
the biallelic marker and true disease locus, and if the
allele frequencies at the marker and disease locus differed
greatly, the sample sizes necessary for the TDT would
be greatly increased. The work undertaken here ad-
dresses the latter assumption, that of multiplicative
GRRs. The existence of multiplicative GRRs is a special
case, since these conditions provide stability in the sense
that Hardy-Weinberg equilibrium (HWE) is maintained
in the disease population. In reality, however, we know
that a disease population can differ greatly from HWE;
for example, in insulin-dependent diabetes mellitus the
distribution of genotypes at the HLA-DRB1 locus differs
significantly from that expected under HWE (Field et al.
1986). I have therefore derived the necessary equations
to compare genomewide ASP linkage analysis with TDT,
for general GRRs. I also compare ASP linkage and TDT
analyses for sample sizes necessary under four standard
and commonly assumed modes of inheritance (MOIs):
multiplicative, additive, common recessive, and common
dominant.
Methods
I here derive the equations of Risch and Merikangas
(1996), for general GRRs. I define the single-locus-spe-
cific penetrances for the disease to be f0, f1, and f2, for
the probability of disease, given genotypes aa, Aa, and
AA, respectively, where A is the putative disease allele.
I will consider two specific GRRs—GRR1 and
GRR2—such that GRRi indicates the relative risk to an
individual carrying i A alleles, compared with that of an
individual carrying none. These GRRs, defined for
, can be written as andf ( 0 GRR  f /f GRR 0 1 1 0 2
.f /f2 0
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Table 1
Case-Control-Type Table for a
Candidate Locus
GENOTYPE
POPULATION AA Aa aa
Affected a b c
Control d e f
Table 2
Penetrance Functions and GRRs for Selected MOIs
PENETRANCE
FUNCTION GRR
MOI f0 f1 f2 GRR1 GRR2
Multiplicative a ag ag2 g g2
Additive a ag 2ag g 2g
Common recessive a a ag 1 g
Common dominant a ag ag g g
NOTE.—a ( 0; and .g 1 1
These quantities can be estimated at candidate loci by
the heterozygous and homozygous odds ratios (ORs),
which can be calculated simply by use of a case-control-
study table, such as table 1. The heterozygous OR (OR1)
and homozygous OR (OR2) are found as follows:
; and , with OR1 providing anOR  bf/ce OR  af/cd1 2
estimate for GRR1 and with OR2 providing an estimate
for GRR2.
Special relationships may exist between GRR1 and
GRR2. Table 2 indicates these, in terms of a background
penetrance parameter a((0) and a genetic penetrance
parameter g(11), for some standard MOIs.
ASP Linkage Analysis
Similarly to Risch and Merikangas (1996), I have as-
sumed the best-case scenario for ASP linkage analy-
sis—that is, a fully informative ( )heterozygosity 1
closely linked ( ) marker. Now, from Suarez et al.v  0
(1978), with ,v  0
1 1V  VA D2 41
P(0 IBD genes/ASP)  [ ]1 124 4(K  V  V )A D2 4
1 VD21
P(1 IBD gene/ASP)   ,[ ]1 122 4(K  V  V )A D2 4
1 3V  VA D2 41
P(2 IBD genes/ASP)  [ ]1 124 4(K  V  V )A D2 4
where is the population prev-2 2K  p f  2pqf  q f2 1 0
alence, p is the allele frequency for allele A and q 
, is the additive21 p V  2pq[p(f  f ) q(f  f )]A 2 1 1 0
variance, and is the dominance2 2 2V  p q (f  2f  f )D 2 1 0
variance.
The expected proportion of alleles shared IBD by an
ASP, Y, can therefore be written as
1 V  VA DY  1 .
1 12[ ]2 4(K  V  V )A D2 4
To calculate the number of ASP families necessary, Risch
and Merikangas (1996) defined the random variable
(RV) Bi, such that if the ASP shares an allele fromB  1i
the ith parent and if it does not. Now,B  1 P(B i i
and (see appendix A). This1)  Y P(B  1)  1 Yi
simplifies under the null hypothesis (H0) of no linkage,
since , and henceV  V  0 P(B  1)  P(B A D i i
. The mean and variance of Bi under H0 are1)  .5
therefore given by 0 and 1, respectively. In a sample of
N families (two parents and two offspring) there are 2N
independent observations of Bi, giving a total mean and
variance, over all families, of 0 and 2N, respectively.
Under the alternative hypothesis, the mean and variance
over all families, in terms of Y, are given by 2N(2Y
and , respectively. With these quantities1) 8NY(1 Y)
and standard normal-distribution theory (see appendix
B), the number of families necessary to achieve 80%
power under any genetic mechanism can be calculated:
2[ ]z  2z Y(1 Y)1a b
N x ,22(2Y 1)
where , with as the cumulative distribu-1z  F (x) F()x
tion function (CDF) of the standard normal distribution,
and where a is the probability of a type I error and b
is the probability of a type II error (i.e., power  1
).b
Table 3 shows the sample sizes needed, for various
MOI and various values of p. A critical value of 2.2 #
105 has been used to determine genomewide signifi-
cance, as suggested by Lander and Kruglyak (1995).
TDT Association and Linkage Analysis Using Singletons
I assume that N families consisting of a single affected
offspring (SAO) plus both parents have been collected.
The unit for use in the TDT is a heterozygous parent
plus SAO, and therefore only heterozygous parents will
ultimately be included in the analysis. The probability
that a parent is heterozygous, given that he or she has
an SAO, is
pq(pf  f  qf )2 1 0h  P(heterozygous/SAO) ,s K
Table 3
Sample Sizes Necessary to Gain 80% Power in ASP Linkage Analysis, in TDT with Singletons, and in TDT with ASPs
g AND p
SAMPLE SIZE NECESSARY TO GAIN 80% POWER
ASP Linkage Analysis
TDT
With Singletons With ASPs
Multiplicative Additive Recessive Dominant Multiplicative Additive Recessive Dominant Multiplicative Additive Recessive Dominant
4.0:
.01 7,912 9,399 2.5 # 108 9,778 523 549 4.3 # 106 562 59 67 7.0 # 105 70
.10 342 813 30,617 1,055 86 123 5,056 153 20 36 866 49
.50 551 2,399 1,022 9,163 103 222 205 712 71 143 104 516
.80 3,737 18,264 4,320 4.0 # 105 291 663 337 9,873 293 518 312 7,810
2.0:
.01 5.5 # 105 5.5 # 105 11010 6.0 # 105 4,154 4,154 3.8 # 107 4,317 1,018 1,018 1.2 # 107 1,083
.10 9,995 9,995 2.2 # 106 19,300 533 533 43,331 766 161 161 13,762 268
.50 4,638 4,638 15,743 57,693 340 340 949 1,861 188 188 431 1,133
.80 22,134 22,134 30,335 2.1 # 106 750 750 976 22,728 553 553 661 15,149
1.5:
.01 8.6 # 106 7.8 # 106 11010 9.0 # 106 16,008 15,550 1.5 # 108 16,487 5,366 5,121 6.1 # 107 5,579
.10 1.3 # 105 62,068 3.4 # 107 2.1 # 105 1,908 1,485 1.7 # 105 2,554 704 490 67,104 1,012
.50 33,428 7,197 1.5 # 105 3.4 # 105 949 464 3,078 4,599 492 237 1,423 2,575
.80 1.3 # 105 24,881 1.9 # 105 1.1 # 107 1,833 816 2,553 51,914 1,156 583 1,509 31,206
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which can be written in terms of GRR1 and GRR2 by
dividing both the numerator and denominator by
f0( 0):
pq(pGRR GRR  q)2 1h  .s 2 2p GRR  2pqGRR  q2 1
The probability that the parent transmits allele A to the
SAO is
t  P(transmit A/heterozygous and SAO)s
pf  qf2 1 .
(pf  f  qf )2 1 0
I define the following RV, Bi, such that if
1/2B  (2pq)i
the parent is heterozygous and A is transmitted, B i
if the parent is heterozygous and a is trans-1/2(2pq)
mitted, and if the parent is homozygous.B  0i
This definition for Bi differs from that described by
Risch and Merikangas (1996), but I believe this to be a
more appropriate definition (M. Iles and D. T. Bishop,
personal communication), since the values for the RV
should not depend on the hypothesis assumed. Under
the null hypothesis of no linkage and no association (the
TDT is a valid test for both, under these conditions),
, , and1/2 1/2P[B  (2pq) ]  pq P[B  (2pq) ]  pqi i
. The mean and the variance for Bi
2 2P(B  0)  p  qi
under H0 are therefore 0 and 1, respectively. In a sample
of N families (two parents and an SAO), there are 2N
independent observations of Bi, giving a total mean and
variance, over all families, of 0 and 2N, respectively.
Under the alternative hypothesis, 1/2P[B  (2pq) ] i
, and1/2h t P[B  (2pq) ]  h (1 t ) P(B  0) s s i s s i
, with hs and ts as defined above. The mean and1 hs
variance under H1 are given by
1/22N(2pq) h (2t  1)s s
and , respectively, summed1 22N(2pq) h [1 h (2t  1) ]s s s
over all N families. With these quantities, the number
of families necessary to achieve 80% power under any
genetic mechanism can be calculated.
22 { ( ) }z 2pq  z h 1 h 2t  1[ ]1a b s s s
N x .2 22h (2t  1)s s
Table 3 illustrates sample sizes needed for a range of
MOIs and values of p. A critical value of 5 # 108 has
been used to determine genomewide significance for the
TDT. This constitutes a Bonferroni correction account-
ing for both alleles at five biallelic markers being tested
(one-sided test) in each of 100,000 genes, with each test
being independent.
TDT Linkage Analysis Using ASPs
In this case I assume that N families consisting of an
ASP plus both parents have been collected. The prob-
ability that a parent is heterozygous, given that it has
an ASP, is
h  P(heterozygous/ASP)p
2 2 2 {pq[(pf  f  qf )  p(f  f )  q(f  f ) ]}/2 1 0 2 1 1 0
4 2 3 2 2 2 2[4p f  4p q(f  f )  p q (f  2f  f )2 2 1 2 1 0
2 2 2 3 2 4 2 8p q f  4pq (f  f )  4q f ] ,1 1 0 0
and the probability that the parent transmits allele A to
an affected offspring is
t  P(transmit A/heterozygous and ASP)p
 [(pf  qf )(pf  f  qf ) pf (f  f )2 1 2 1 0 2 2 1
2 2 qf (f  f )]/[(pf  f  qf )  p(f  f )1 1 0 2 1 0 2 1
2 q(f  f ) ] .1 0
The same definition for the RV Bi as for the singleton
case was used. Under the null hypothesis of no linkage
(the TDT is valid only as a test for linkage whenmultiple
affected offspring are used), ,1/2P[B  (2pq) ]  pqi
, and . The1/2 2 2P[B  (2pq) ]  pq P(B  0)  p  qi i
mean and variance under H0 are therefore given by 0
and 1, respectively. In a sample of N families (two par-
ents and two offspring) there are 4N independent ob-
servations of Bi, giving a total mean and variance, over
all families, of 0 and 4N, respectively. Under the alter-
native hypothesis, ,1/2P[B  (2pq) ]  h t P[B  i p p i
, and , with hp
1/2(2pq) ]  h (1 t ) P(B  0)  1 hp p i p
and tp as defined above. The mean and variance under
H1 are given by and
1/24N(2pq) h (2t  1)p p
, respectively, summed1 24N(2pq) h [1 h (2t  1) ]p p p
over the N families. With these quantities the number
of families necessary to achieve 80% power under any
genetic mechanism can be calculated:
22 { }[ ]z 2pq  z h 1 h (2t  1)1a b p p p
N x .2 24h (2t  1)p p
Table 3 illustrates sample sizes needed for a range of
MOIs and values of p. A critical value of 5 # 108 has
been used to determine genomewide significance.
Results
The results in table 3 show that, in line with results
from Risch and Merikangas (1996), the number of fam-
ilies necessary to perform a genomewide screen using the
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Table 4
Values of g for Which Loci Can Be Detected with 80%
Power in a Genomewide TDT Using Singletons (N 
)1, 000
VALUE OF g FOR WHICH LOCUS CAN BE DETECTED
WITH 80% POWER
p Multiplicative Additive Recessive Dominant
.01 3.114 3.150 212.4 3.182
.10 1.707 1.653 8.072 1.853
.50 1.484 ∼1.000 1.968 2.875
.80 1.785 ∼1.000 1.981 11010
TDT (singletons or sib-pairs) is smaller, in all cases, than
that necessary for standard ASP linkage analysis. This
observation holds true independently of the MOI or the
relative values of GRR1 and GRR2 that are assumed.
Similarly, it also has been found that the number of
families necessary to perform the genomewide TDT us-
ing affected pairs is fewer, in all cases, than that necessary
for singletons. For low values of p, the relative difference
between using families with ASPs rather than those with
an affected singleton is as large as fourfold (increasing
as the value for g increases). With the existence of a rare
disease allele, therefore, the collection of ASPs would
perhaps be more advantageous, since less genotyping
would be necessary to gain the same power of study.
For larger values (1.5) of p, the relative difference is
much less, and therefore it could be argued that the
advantage of reduced genotyping is offset by the in-
creased difficulty in collecting ASPs versus collecting sin-
gletons. Another consideration is that, with singletons,
the TDT is valid as a test for both association and linkage
but that, with ASPs, it is valid only as a test for linkage
(Spielman and Ewens 1996).
General observations on the effect of MOI on sample
size include the intuitive relationship between additive
and multiplicative GRRs. Specifically, for the sam-g 1 2
ple sizes necessary under a multiplicative MOI are less
than those under an additive model. For additiveg  2
and multiplicative models are the same—and hence so
are the sample sizes that are necessary—and for g ! 2
the sample sizes necessary under the additive MOI are
smaller. A relationship also exists between the common
recessive and common dominant MOIs based on p. For
small values of p, the sample sizes needed under a dom-
inant model are smaller than those needed under a
recessive model, and the reverse is true for large values
of p.
The most significant result illustrated in table 3 is the
indication that the pattern of GRR at the disease locus
may change—by several orders of magnitude, in some
cases—the sample size necessary to perform a genome-
wide TDT (or ASP linkage). This result has important
consequences for sample collection and in determining
what type of effects could realistically be expected to be
identified in such a study. For example, if andp  .01
, the number of families necessary to perform ag  4.0
genomewide TDT with singletons varies from ∼550, in
the multiplicative, additive, and common-dominant
cases, to 4.3# 106 if the MOI is common recessive. As
another illustration, table 4 shows the g values for which
loci could be detected with 80% power when 1,000
SAO-parent trios are used. It can be seen that a sample
size of 1,000 would be sufficient to detect loci with g’s
of fairly small magnitude (∼1.00–3.15) under multipli-
cative and additive models—and that this number would
be similarly sufficient under a common-recessive model
if and under a common-dominant model ifp x .5
. If, however, small-effect loci existed either withp X .5
a recessive-type inheritance with or with a dom-p ! .5
inant model with , they would almost definitely bep 1 .5
missed.
Discussion
The four specific inheritance models considered here
are obviously not exhaustive, but they clearly illustrate
that patterns of GRRs at disease loci have substantial
implications for the necessary sample size. We will, of
course, rarely know all the loci involved and their in-
heritance patterns, and therefore a sample-size estimate
based on a known MOI is of little value, although one
application may be to use estimates for GRRs at any
candidate-gene loci, to ensure that these at least could
be detected/replicated. By considering a sensible range
of inheritance patterns, however, and creating a table
such as table 3, we can calculate highly informative
guidelines on necessary sample size for unknown loci.
Once a sample size has been chosen and collected, a
table such as table 4 would indicate the magnitudes of
gene effects that could be detected with 80% power.
Such information, indicating what a study is likely (and
unlikely) to detect, is of great value and should lead to
a reduction in the number of false-negative conclusions.
As mentioned above, Mu¨ller-Myhsok and Abel (1997)
showed that, if less than maximum linkage disequilib-
rium exists between marker and true disease locus, and
if differences between the relative allele frequencies exist,
then the sample size necessary increases. These possi-
bilities must also, therefore, be taken into account when
one is determining a sufficient sample size. As Risch and
Merikangas (1997) point out in their response, however,
the outlook may be optimistic. They mention two par-
ticular disease-locus regions, the apoE region (involved
in Alzheimer disease) and the insulin VNTR region on
chromosome 11p, in which both strong linkage dis-
equilibrium and comparable allele frequencies exist (Ju-
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lier et al. 1991; Chartier-Harlin et al. 1994; Bennett et
al. 1995). The issue, nevertheless, should not be dis-
missed, and any knowledge of the degree of linkage dis-
equilibrium across the genome should be considered,
especially within any candidate genes.
The equations presented here involve the assumption
that, conditional on the genotype at the trait locus in
question, disease occurrences in sib pairs are independ-
ent. This is unlikely to be the case for complex traits,
which are influenced by several genetic loci and envi-
ronmental factors. Clearly, this assumption has no in-
fluence on sample sizes calculated for TDT singleton
analysis, since sib pairs are not involved. For ASP linkage
analysis using allele sharing or TDT, however, violation
of the assumption could influence the calculations, and
this may be worth considering when one is drawing
comparisons.
The g values considered here are small (4.0, 2.0, and
1.5) and correspond to a range for ls,
1[ 1 ( V A2
, from just over 1.0 to 1.5, depending on the1 2V )/K ]D4
value of p and on the inheritance model. These values
are small but are likely to be reasonable for the disease
loci of truly polygenic diseases. Such complex—and in-
variably common—diseases are where standard ASP ge-
nomewide screening is currently producing fewer an-
swers—and where, arguably, genomewide TDT will be
most useful. On a positive note, these diseases do have
the added advantage of being easy to collect in large
numbers, especially among SAO families, because of
their relatively high prevalence. The possibility of a new,
more sensitive genomewide screening method should
not, however, be viewed as the means to detect all disease
loci. The genomewide approach bypasses the need for
any knowledge of the biological system or environmen-
tal interactions and, as such, will miss any disease loci
that interact and are only of consequence together.
The future will provide the technology to perform
genomewide TDT studies, and in the meanwhile we can
prepare by initiating family collections or by expanding
current ones. With information both on GRR patterns,
as outlined in this paper, and on linkage disequilibrium
in the genome as it becomes known, guidelines on the
number of families necessary can be calculated. The ge-
nomewide TDT screen will be an extremely useful tool
in the future genetic study of polygenic diseases—but it
should be viewed as one approach among the many that
we have already.
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Appendix A
Calculation of under H1 for Standard ASP Link-P(B  1)i
age Analysis
I seek to show that andP(B  1)  Y P(B i i
, where if the ASP shares an allele1)  1 Y B  1i
from the ith parent and if it does not and whereB  1i
Y is the expected proportion of alleles shared IBD by an
ASP.
In an ASP family, let i and j be the two parents. Then,
2
n ( )Y  P n  n  n ,i j
n0 2
where n is the number of alleles shared IBD by the ASP
and where ni and nj are the number of alleles (0 or 1)
shared from parent i and j, respectively.
Each parent transmits alleles independently and iden-
tically, so we can write
0 1
Y  P(n  n  0) P(n  n  1)i j i j2 2
2
 P(n  n  2)i j2
1 [ ] P(n  0)P(n  1) P(n  1)P(n  0)i j i j2
P(n  1)P(n  1)i j
1 [ ] P(n  0)P(n  1) P(n  1)P(n  0)i i i i2
P(n  1)P(n  1) .i i
Now, andP(n  0)  P(B  1) P(n  1)  P(B i i i i
, such that1)
2Y  P(B  1)P(B  1) P (B  1)i i i
[ ] P(B  1) P(B  1) P(B  1)P(B  1) .i i i i
Hence, and , sinceP(B  1)  Y P(B  1)  1 Yi i
.P(B  1) P (B  1)  1i i
Appendix B
Calculation of the Number of Families Necessary for
Genomewide Screens
Let H0 be
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xN
B  B ∼ norm(0, xN) ,i
i0
and let H1 be
xN
2B  B ∼ norm(mxN, j xN) ,i
i0
where m and j2 are the mean and variance, respectively,
of a single observation of Bi under H1 and where x is
the number of observations of Bi per family.
We require that and thatP(type I error) a
; that is, . First, weP(type II error) b power  (1 b)
will therefore accept H0 at the a level, in a one-sided
test, if ; that is, , [(B 0) / xN ] ! z B ! z xN1a 1a
where , with being the CDF of the1z  F (1 a) F()(1a)
standard normal distribution.
Second, to achieve a type II error of b, we require that
, which, after being stan-P(B ! z xN/H is true) ≤ b1a 1
dardized, becomes
z xN  mxN1a
F ≤ b ,( )j xN
which, after being rearranged, can be written as
. In the case of standard ASP2 2N x [(z  jz ) /xm ]1a b
linkage analysis, , , ,2x  2 m  2Y 1 j  4Y(1 Y)
, and (i.e., 80% power). For a5a  2.2# 10 b  .2
genomewide screen using the TDT with singletons,
, ,1/2 2 1x  2 m  (2pq) h (2t  1) j  (2pq) h [1s s s
, , and . Similarly, for2 8h (2t  1) ] a  5# 10 b  .2s s
TDT with ASPs, , ,1/2 2x  4 m  (2pq) h (2t  1) j p p
, , and .1 2 8(2pq) h [1 h (2t  1) ] a  5# 10 b  .2p p p
References
Bennett ST, Lucassen AM, Gough SCL, Powell EE, Undlien
DE, Pritchard LE, Merriman ME, et al (1995) Susceptibility
to human type 1 diabetes at IDDM2 is determined by tan-
dem repeat variation at the insulin gene minisatellite locus.
Nat Genet 9:284–292
Chartier-Harlin M-C, Parfitt M, Legrain S, Pe´rez-Tur J, Brous-
seau T, Evans A, Berr C, et al (1994) Apolipoprotein E, e4
allele as a major risk factor for sporadic early and late-onset
forms of Alzheimer’s disease: analysis of the 19q13.2 chro-
mosomal region. Hum Mol Genet 3:569–574
Field LL, Fothergill-Payne C, Bertrams J, Baur MP (1986)
HLA-DR effects in a large German IDDM dataset. Genet
Epidemiol Suppl 1:323–328
Julier C, Hyer RN, Davies J, Merlin F, Soularue P, Briant L,
Cathelineau G, et al (1991) Insulin-IGF2 region on chro-
mosome 11p encodes a gene implicated in HLA-DR4-de-
pendent diabetes susceptibility. Nature 354:155–159
Lander E, Kruglyak L (1995) Genetic dissection of complex
traits: guidelines for interpreting and reporting linkage re-
sults. Nat Genet 11:241–247
Mu¨ller-Myhsok B, Abel L (1997) Genetic analysis of complex
disease. Science 275:1328–1329
Risch N, Merikangas K (1996) The future of genetic studies
of complex human diseases. Science 273:1516–1517
——— (1997) Genetic analysis of complex disease. Science
275:1329–1330
Spielman RS, Ewens WJ (1996) The TDT and other family-
based tests for linkage disequilibrium and association. Am
J Hum Genet 59:983–989
Spielman RS, McGinnis RE, Ewens WJ (1993) Transmission
test for linkage disequilibrium: the insulin gene region and
insulin-dependent diabetes mellitus (IDDM). Am J HumGe-
net 52:506–516
Suarez BK, Rice J, Reich T (1978) The generalised sib pair
IBD distribution: its use in the detection of linkage. Ann
Hum Genet 42:87–94
